Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability.The main aim of this study was to improve the oral bioavailability of raloxifene (RXF), a selective estrogen receptor modulator, by incorporation into solid lipid nanoparticles (SLN).  RXF-loaded SLN was prepared by homogenization-sonication technique and characterized through physicochemical, pharmacokinetic, and cytotoxicity studies.  The optimized SLN formulation exhibited a spherical shape with average size around 140 nm, easing its transport across the lymphatic system.  Augmentation in the profiles of C(max) (308%) and AUC (270%) indicated a significant enhancement in the rate and extent of bioavailability by SLN formulations compared to free drug.  In vitro cytotoxicity study performed in NIH-3T3 cells revealed that RXF-SLN was cytocompatible, and SLN remained unchanged during the freeze-drying process.  In conclusion, SLN provides a promising platform for the pronounced enhancement of RXF bioavailability.
SLN
Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability.The main aim of this study was to improve the oral bioavailability of raloxifene (RXF), a selective estrogen receptor modulator, by incorporation into solid lipid nanoparticles (SLN).  RXF-loaded SLN was prepared by homogenization-sonication technique and characterized through physicochemical, pharmacokinetic, and cytotoxicity studies.  The optimized SLN formulation exhibited a spherical shape with average size around 140 nm, easing its transport across the lymphatic system.  Augmentation in the profiles of C(max) (308%) and AUC (270%) indicated a significant enhancement in the rate and extent of bioavailability by SLN formulations compared to free drug.  In vitro cytotoxicity study performed in NIH-3T3 cells revealed that RXF-SLN was cytocompatible, and SLN remained unchanged during the freeze-drying process.  In conclusion, SLN provides a promising platform for the pronounced enhancement of RXF bioavailability.
SLN
Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability.The main aim of this study was to improve the oral bioavailability of raloxifene (RXF), a selective estrogen receptor modulator, by incorporation into solid lipid nanoparticles (SLN).  RXF-loaded SLN was prepared by homogenization-sonication technique and characterized through physicochemical, pharmacokinetic, and cytotoxicity studies.  The optimized SLN formulation exhibited a spherical shape with average size around 140 nm, easing its transport across the lymphatic system.  Augmentation in the profiles of C(max) (308%) and AUC (270%) indicated a significant enhancement in the rate and extent of bioavailability by SLN formulations compared to free drug.  In vitro cytotoxicity study performed in NIH-3T3 cells revealed that RXF-SLN was cytocompatible, and SLN remained unchanged during the freeze-drying process.  In conclusion, SLN provides a promising platform for the pronounced enhancement of RXF bioavailability.
SLN
Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability.The main aim of this study was to improve the oral bioavailability of raloxifene (RXF), a selective estrogen receptor modulator, by incorporation into solid lipid nanoparticles (SLN).  RXF-loaded SLN was prepared by homogenization-sonication technique and characterized through physicochemical, pharmacokinetic, and cytotoxicity studies.  The optimized SLN formulation exhibited a spherical shape with average size around 140 nm, easing its transport across the lymphatic system.  Augmentation in the profiles of C(max) (308%) and AUC (270%) indicated a significant enhancement in the rate and extent of bioavailability by SLN formulations compared to free drug.  In vitro cytotoxicity study performed in NIH-3T3 cells revealed that RXF-SLN was cytocompatible, and SLN remained unchanged during the freeze-drying process.  In conclusion, SLN provides a promising platform for the pronounced enhancement of RXF bioavailability.
SLN
Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability.The main aim of this study was to improve the oral bioavailability of raloxifene (RXF), a selective estrogen receptor modulator, by incorporation into solid lipid nanoparticles (SLN).  RXF-loaded SLN was prepared by homogenization-sonication technique and characterized through physicochemical, pharmacokinetic, and cytotoxicity studies.  The optimized SLN formulation exhibited a spherical shape with average size around 140 nm, easing its transport across the lymphatic system.  Augmentation in the profiles of C(max) (308%) and AUC (270%) indicated a significant enhancement in the rate and extent of bioavailability by SLN formulations compared to free drug.  In vitro cytotoxicity study performed in NIH-3T3 cells revealed that RXF-SLN was cytocompatible, and SLN remained unchanged during the freeze-drying process.  In conclusion, SLN provides a promising platform for the pronounced enhancement of RXF bioavailability.
SLN
Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability.The main aim of this study was to improve the oral bioavailability of raloxifene (RXF), a selective estrogen receptor modulator, by incorporation into solid lipid nanoparticles (SLN).  RXF-loaded SLN was prepared by homogenization-sonication technique and characterized through physicochemical, pharmacokinetic, and cytotoxicity studies.  The optimized SLN formulation exhibited a spherical shape with average size around 140 nm, easing its transport across the lymphatic system.  Augmentation in the profiles of C(max) (308%) and AUC (270%) indicated a significant enhancement in the rate and extent of bioavailability by SLN formulations compared to free drug.  In vitro cytotoxicity study performed in NIH-3T3 cells revealed that RXF-SLN was cytocompatible, and SLN remained unchanged during the freeze-drying process.  In conclusion, SLN provides a promising platform for the pronounced enhancement of RXF bioavailability.
SLN